Search - tctmd.com

Displaying 161 - 180 of 392

Sort: Relevancy | Date

News Daily News

Medtronic’s HeartWare HVAD Recalled for Pump Weld Defect

L.A. McKeown

April 29, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ARCH 2022

Left Ventricular Remodeling & Device Therapy in HF

Presenter: Justin Vader

April 23, 2022

Presentation ARCH 2022

Interventional Heart Failure: Present and Future State

Presenter: Douglas Horstmanshof

April 23, 2022

Presentation ARCH 2022

Heart Failure Remote Monitoring

Presenter: Justin Vader

April 23, 2022

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

Presentation ARCH 2022

Candidate Selection for Advanced Heart Failure Therapies: 2022

Presenter: Gregory Ewald

April 23, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Todd Neale

April 20, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Daily News

Cardiac Complications Higher After COVID-19 Than Vaccination

Shelley Wood

April 14, 2022

News Daily News

Myopericarditis No More Common After COVID-19 Shots Than Other Vaccines

Caitlin E. Cox

April 12, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

Presentation ACC 2022

SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure

Presenter: Justin Ezekowitz

April 04, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Advertisement

Medtronic’s HeartWare HVAD Recalled for Pump Weld Defect

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Left Ventricular Remodeling & Device Therapy in HF

Interventional Heart Failure: Present and Future State

Heart Failure Remote Monitoring

First Things First – Pharmacotherapy for HFrEF

Candidate Selection for Advanced Heart Failure Therapies: 2022

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Infertility in Women Linked to Subsequent Risk of HFpEF

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Cardiac Complications Higher After COVID-19 Than Vaccination

Myopericarditis No More Common After COVID-19 Shots Than Other Vaccines

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content